Equities Analysts Issue Forecasts for OLMA FY2029 Earnings

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Research analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of Olema Pharmaceuticals in a report released on Wednesday, March 19th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings of ($2.41) per share for the year. HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.33) per share.

Separately, Oppenheimer restated an “outperform” rating and set a $25.00 target price (down from $30.00) on shares of Olema Pharmaceuticals in a report on Wednesday.

Olema Pharmaceuticals Price Performance

Shares of Olema Pharmaceuticals stock opened at $4.23 on Thursday. The stock has a market cap of $242.37 million, a P/E ratio of -1.93 and a beta of 2.11. The stock’s 50 day simple moving average is $5.09 and its 200-day simple moving average is $8.35. Olema Pharmaceuticals has a 1-year low of $3.94 and a 1-year high of $16.62.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its earnings results on Tuesday, March 18th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.12.

Institutional Trading of Olema Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS purchased a new stake in shares of Olema Pharmaceuticals during the fourth quarter worth $30,000. Hsbc Holdings PLC purchased a new stake in shares of Olema Pharmaceuticals during the fourth quarter worth $58,000. Teacher Retirement System of Texas purchased a new stake in shares of Olema Pharmaceuticals during the fourth quarter worth $60,000. Vontobel Holding Ltd. purchased a new stake in shares of Olema Pharmaceuticals during the fourth quarter worth $62,000. Finally, Virtus ETF Advisers LLC increased its position in shares of Olema Pharmaceuticals by 43.1% during the fourth quarter. Virtus ETF Advisers LLC now owns 10,579 shares of the company’s stock worth $62,000 after acquiring an additional 3,185 shares during the period. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Insider Activity

In other news, major shareholder Bain Capital Life Sciences Inv bought 300,000 shares of the business’s stock in a transaction on Wednesday, January 8th. The shares were bought at an average price of $5.76 per share, with a total value of $1,728,000.00. Following the completion of the transaction, the insider now directly owns 7,800,000 shares in the company, valued at $44,928,000. This trade represents a 4.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 19.40% of the company’s stock.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.